title: [Residual ovary syndrome--significance of medical therapy (author's transl)].
abstract: Today, hysterectomy internationally is nearly as frequent as appendectomy. In approx. 1% of all hysterectomies (vaginal or abdominal) where one or both ovaries are left, the residual ovary syndrome is found after an average period of slightly over five years. Predominant symptoms are diffused abdominal pain and palpable tumour of the adnexae. More rarely, only one symptom alone is found. Up to today, treatment of choice has been an operation which, due to the always present adhesions, is a severe one. The results described in this paper suggest the probatory treatment with high-dosage dept-gestagens (Depo-Provera). In 71% of the cases the tumour disappeared completely under this treatment and in 39% the pain. In further 21% a diminution of the tumour could be seen and in 41% an improvement of the pain. Only in 8% did the tumour and in 20% the pain not respond. There was no case where there was a deterioration. The proposed therapy is cheaper and less dangerous than the usual surgical treatment and therefore should always be performed probatorily before an operation.
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D010049:Ovarian Diseases / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D010146:Pain; D011183:Postoperative Complications; D011372:Progestins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D011372:Progestins
vernacular_title: Bedeutung der medikamentösen Therapie des "syndrome de l'ovaire restant".